Presented at the European Respiratory Society meeting in Barcelona, the announcement marks the first time artificial intelligence (AI) using convolutional neural networks has been used to analyse trial data involving the IPF.
The AI-based Lung8 imaging software picked up differences in response between patients who had an experimental drug compared with those who took a placebo – key information that traditional analysis had failed to find, the company noted.
